News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
No shortage of an FDA approved scorpion anti-venom biopharmaceutical is envisioned after a manufacturing facility in Mexico received a Warning Letter, US distributor Rare Disease Therapeutics says.
Hospira has predicted its biosimilar Retacrit will be approved by the US FDA from late 2016, making it among the first wave of biosimilars to be sold in the US.
WuXi PharmaTech says it has no intention using stainless steel tanks at its new cell therapy manufacturing facility in Philadelphia, Pennsylvania.